Robust Preclinical Evidence in Somatic Cell Genome Editing: A Key Driver of Responsible and Efficient Therapeutic Innovations
M. Bittlinger, J. Schwietering, D. Strech
This paper analyzes 46 preclinical SCGE studies and finds they lack key robustness elements, suggesting improved reporting standards and NIH criteria are needed for reliable translational research.
bioRxiv · Sep 9, 2020Scientific Communication & Education